Chronic lymphocytic leukaemia+2
RecruitingClinical Trial of Human Normal Immunoglobulin to Prevent Infections in Patients with Secondary Antibody Deficiency due to CLL, Multiple Myeloma or Non‑Hodgkin Lymphoma
Clinical Trial of Human Normal Immunoglobulin to Prevent Infections in Patients with Secondary Antibody Deficiency due to CLL, Multiple Myeloma or Non‑Hodgkin Lymphoma
- Disease:Chronic lymphocytic leukaemiaNon-Hodgkin's lymphoma+1
- Substances:Human Normal Immunoglobulin
Spain- Participants:18–64 years · 65+ years
- Substances:Human Normal Immunoglobulin
- Sponsor:Grifols Therapeutics LLC



